Saturday, July 11, 2026

Drug profile · INN

levonordefrin

levonordefrin (MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN) is a adrenergic receptor alpha-2 agonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — levonordefrin
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

levonordefrin (MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN) is a adrenergic receptor alpha-2 agonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN levonordefrin
Brand MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Mechanism Adrenergic receptor alpha-2 agonist
Target Adrenergic receptor alpha-2
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Adrenergic receptor alpha-2 agonist

Primary target: Adrenergic receptor alpha-2

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. brimonidine tartrate Adrenergic receptor alpha-2 agonist
  2. clonidine hydrochloride Adrenergic receptor alpha-2 agonist
  3. dexmedetomidine hydrochloride Adrenergic receptor alpha-2 agonist
  4. guanfacine hydrochloride Adrenergic receptor alpha-2 agonist
  5. methyldopa Adrenergic receptor alpha-2 agonist
  6. methyldopate hydrochloride Adrenergic receptor alpha-2 agonist

Frequently asked questions

What is levonordefrin?

levonordefrin (MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN) is a adrenergic receptor alpha-2 agonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for levonordefrin?

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a marketed brand name for levonordefrin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of levonordefrin?

levonordefrin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.